OncoLyika have been involved with the commercialisation of intellectual property on drug developed by the University of Greenwich.
The University of Greenwich submitted a patent application in the first instance form a portfolio of intellectual property describing innovative drug delivery strategies for moving large biologically active molecules (replacement genes, antisense agents, siRNA, aptamers and proteins, collectively referred to as biologics) into the cytosol of mammalian cells.
The innovation has been supported a number of organisations and was well received at the 9th annual meeting of the Oligonucleotide Therapeutic Society. As a partner of the project, OncoLyika engaged to help commercialise this intellectual property with the below poster. The partnership work undertaken by OncoLytika has attracted the attention of many major pharmaceutical companies such as AstraZenica and GlaxoSmithKline as well as the academic community.
For more information see here.